The Ensign Group, Inc. $ENSG Stake Lifted by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its stake in shares of The Ensign Group, Inc. (NASDAQ:ENSG) by 515.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 16,446 shares of the company’s stock after purchasing an additional 13,774 shares during the period. Hsbc Holdings PLC’s holdings in The Ensign Group were worth $2,873,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Baillie Gifford & Co. lifted its position in The Ensign Group by 62.1% in the fourth quarter. Baillie Gifford & Co. now owns 4,569,254 shares of the company’s stock worth $795,964,000 after purchasing an additional 1,750,645 shares during the period. Norges Bank acquired a new position in shares of The Ensign Group during the 4th quarter valued at $134,660,000. Turtle Creek Asset Management Inc. acquired a new position in shares of The Ensign Group during the 3rd quarter valued at $78,840,000. Wasatch Advisors LP increased its position in shares of The Ensign Group by 6.0% during the 2nd quarter. Wasatch Advisors LP now owns 3,558,675 shares of the company’s stock valued at $548,961,000 after purchasing an additional 199,983 shares during the period. Finally, T. Rowe Price Investment Management Inc. raised its stake in shares of The Ensign Group by 28.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 683,884 shares of the company’s stock worth $119,133,000 after buying an additional 151,792 shares in the last quarter. Institutional investors own 96.12% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Weiss Ratings lowered The Ensign Group from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 16th. Wall Street Zen raised The Ensign Group from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Royal Bank Of Canada reiterated an “outperform” rating on shares of The Ensign Group in a research report on Tuesday, June 9th. Finally, Zacks Research downgraded shares of The Ensign Group from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $216.75.

The Ensign Group Price Performance

NASDAQ ENSG opened at $168.59 on Friday. The Ensign Group, Inc. has a fifty-two week low of $134.79 and a fifty-two week high of $218.00. The stock’s 50-day moving average is $166.61 and its two-hundred day moving average is $184.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.56 and a quick ratio of 1.56. The firm has a market cap of $9.85 billion, a P/E ratio of 27.46, a price-to-earnings-growth ratio of 1.65 and a beta of 0.69.

The Ensign Group (NASDAQ:ENSG) last released its quarterly earnings results on Thursday, April 30th. The company reported $1.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.06. The company had revenue of $1.39 billion during the quarter, compared to the consensus estimate of $1.40 billion. The Ensign Group had a return on equity of 16.78% and a net margin of 6.89%.The firm’s revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.52 EPS. The Ensign Group has set its FY 2026 guidance at 7.480-7.620 EPS. On average, analysts anticipate that The Ensign Group, Inc. will post 6.82 earnings per share for the current fiscal year.

The Ensign Group Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.065 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $0.26 dividend on an annualized basis and a yield of 0.2%. The Ensign Group’s dividend payout ratio is presently 4.23%.

Insider Buying and Selling

In other The Ensign Group news, Director John O. Agwunobi sold 392 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $199.97, for a total transaction of $78,388.24. Following the transaction, the director owned 9,295 shares in the company, valued at $1,858,721.15. This trade represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry M. Smith sold 700 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $164.28, for a total value of $114,996.00. Following the transaction, the director owned 21,352 shares in the company, valued at approximately $3,507,706.56. This trade represents a 3.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,892 shares of company stock valued at $340,591 in the last ninety days. Company insiders own 4.00% of the company’s stock.

About The Ensign Group

The Ensign Group, Inc is a diversified provider of post-acute healthcare services in the United States, operating a network of skilled nursing, assisted living, independent living, home health and hospice care centers. The company’s model emphasizes integrated care by employing multidisciplinary teams—including nursing staff, therapists and physicians—to deliver personalized rehabilitation and long-term care services for seniors and other patients recovering from injury, illness or surgery.

Through its owned and managed centers, The Ensign Group offers a broad spectrum of rehabilitation services such as physical, occupational and speech therapy.